share_log

HC Wainwright & Co. Maintains Buy on Rani Therapeutics Hldgs, Lowers Price Target to $9

Benzinga ·  Aug 17 01:28  · Ratings

HC Wainwright & Co. analyst Mitchell Kapoor maintains Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and lowers the price target from $13 to $9.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment